Compare Torrent Pharma with Suven Life Sciences - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs SUVEN LIFE SCIENCES - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA SUVEN LIFE SCIENCES TORRENT PHARMA/
SUVEN LIFE SCIENCES
 
P/E (TTM) x 39.1 -92.5 - View Chart
P/BV x 9.9 1.5 682.2% View Chart
Dividend Yield % 0.6 1.6 38.9%  

Financials

 TORRENT PHARMA   SUVEN LIFE SCIENCES
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
SUVEN LIFE SCIENCES
Mar-19
TORRENT PHARMA/
SUVEN LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,964338 581.6%   
Low Rs1,245169 734.9%   
Sales per share (Unadj.) Rs453.452.1 869.8%  
Earnings per share (Unadj.) Rs25.86.8 377.5%  
Cash flow per share (Unadj.) Rs62.38.6 726.8%  
Dividends per share (Unadj.) Rs17.001.50 1,133.3%  
Dividend yield (eoy) %1.10.6 179.1%  
Book value per share (Unadj.) Rs279.265.3 427.6%  
Shares outstanding (eoy) m169.22127.28 133.0%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x3.54.9 72.8%   
Avg P/E ratio x62.237.1 167.6%  
P/CF ratio (eoy) x25.829.6 87.1%  
Price / Book Value ratio x5.73.9 148.0%  
Dividend payout %65.922.0 300.2%   
Avg Mkt Cap Rs m271,51332,272 841.3%   
No. of employees `00013.61.1 1,256.7%   
Total wages/salary Rs m14,038661 2,123.1%   
Avg. sales/employee Rs Th5,642.66,132.2 92.0%   
Avg. wages/employee Rs Th1,032.4611.1 168.9%   
Avg. net profit/employee Rs Th320.9803.5 39.9%   
INCOME DATA
Net Sales Rs m76,7286,635 1,156.4%  
Other income Rs m571242 235.5%   
Total revenues Rs m77,2996,877 1,124.0%   
Gross profit Rs m19,8311,604 1,236.2%  
Depreciation Rs m6,177221 2,789.9%   
Interest Rs m5,03838 13,362.1%   
Profit before tax Rs m9,1871,587 578.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5700-   
Tax Rs m1,254718 174.6%   
Profit after tax Rs m4,363869 501.8%  
Gross profit margin %25.824.2 106.9%  
Effective tax rate %13.645.2 30.2%   
Net profit margin %5.713.1 43.4%  
BALANCE SHEET DATA
Current assets Rs m50,3756,232 808.3%   
Current liabilities Rs m51,6531,490 3,466.4%   
Net working cap to sales %-1.771.5 -2.3%  
Current ratio x1.04.2 23.3%  
Inventory Days Days9286 106.5%  
Debtors Days Days6883 82.7%  
Net fixed assets Rs m83,6484,043 2,068.8%   
Share capital Rs m846127 664.7%   
"Free" reserves Rs m46,3978,183 567.0%   
Net worth Rs m47,2448,310 568.5%   
Long term debt Rs m39,12918 219,827.0%   
Total assets Rs m141,20910,389 1,359.2%  
Interest coverage x2.843.1 6.6%   
Debt to equity ratio x0.80 38,666.5%  
Sales to assets ratio x0.50.6 85.1%   
Return on assets %6.78.7 76.2%  
Return on equity %9.210.5 88.3%  
Return on capital %12.319.5 63.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m22,1035,622 393.2%   
Fx outflow Rs m5,5221,799 306.8%   
Net fx Rs m16,5813,822 433.8%   
CASH FLOW
From Operations Rs m17,981356 5,057.9%  
From Investments Rs m-2,413-279 866.0%  
From Financial Activity Rs m-13,145-225 5,839.4%  
Net Cashflow Rs m2,380-148 -1,606.1%  

Share Holding

Indian Promoters % 71.5 63.4 112.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 0.0 -  
FIIs % 12.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 36.5 24.1%  
Shareholders   26,511 37,287 71.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   GSK PHARMA  JUBILANT PHARMOVA   DIVIS LABORATORIES  IPCA LABS  NATCO PHARMA  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

4 Reasons Why Sensex Surged 848 Points Today(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


May 17, 2021 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS